Mitophagy in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive solid malignancies, is characterized by the presence of oncogenic KRAS mutations, poor response to current therapies, prone to metastasis, and a low 5-year overall survival rate. Macroautophagy (herein referred to as autophagy) is a...
Main Authors: | Yangchun Xie, Jiao Liu, Rui Kang, Daolin Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.616079/full |
Similar Items
-
The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer
by: Rozana Abdul Rahman, et al.
Published: (2021-07-01) -
Mitophagy Receptors in Tumor Biology
by: Yangchun Xie, et al.
Published: (2020-11-01) -
Pancreatic Cancer Associated Fibroblasts (CAF): Under-Explored Target for Pancreatic Cancer Treatment
by: Jeffrey Norton, et al.
Published: (2020-05-01) -
Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma
by: Vida Karimnia, et al.
Published: (2021-08-01) -
Screening for Pancreatic Cancer: Current Status and Future Directions
by: Akshjot Puri, et al.
Published: (2017-11-01)